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S.D. Hobbs,1* M.E. Thomas2 and A.W. Bradbury11University Department of Vascular Surgery, and 2Department of Nephrology, Birmingham Heartlands and
Solihull NHS Trust (Teaching), Birmingham, UKThe Heart Outcomes Prevention Evaluation (HOPE) study has provided evidence for the use of ramipril for secondary
cardiac prevention for patients with peripheral arterial disease. Despite this many vascular surgeons and general
practitioners are reluctant to prescribe ACE inhibitors in a group of patients perceived to have a high incidence of renal
artery stenosis. This review aims to review the pathophysiology of the renin–angiotensin system and make evidence based
recommendations for commencing ACE inhibitors as part of a comprehensive delivery of best medical therapy to patients
with peripheral arterial disease.Keywords: Peripheral arterial disease; Angiotensin converting enzyme inhibitors; Renal artery stenosis.Introduction
Best medical therapy (BMT) comprising risk factor
modification and drug therapy remains the mainstay
of treatment for the great majority patients with
peripheral arterial disease (PAD), with surgical and
endovascular intervention reserved for those with life
and limb-threatening complications.1 Angiotensin-
converting enzyme (ACE) inhibitors have a well-
established role in the treatment of heart failure,
hypertension, myocardial infarction (MI) and chronic
renal insufficiency (CRF).2–4 In addition, the heart
outcomes prevention evaluation (HOPE) study has
provided level 1 evidence to support the use of
ramipril for secondary cardiac prevention in patients
with PAD.5 Despite this, there has been reluctance on
the part of vascular surgeons to initiate ACE inhibitor
therapy in a group perceived at high risk of pharma-
cological nephrectomy as a result of coexisting renal
artery disease. In this article we aim to review theing author. Mr Simon Hobbs, Vascular Research
ersity Department of Vascular Surgery, Research
coln House, Birmingham Heartlands and Solihull
eaching), Bordesley Green East, Birmingham B9 6SS,
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0573+ 10 $35.00/0 q 2004 Elsevier Ltd. All rights reserevidence for the use of ACE inhibitors in PAD, outline
their mechanism of action and discuss how this
treatment can be safely implemented into vascular
surgical practice.Methods
A search of MEDLINE (1966 to 2003) was performed to
identify articles relating to the renin–angiotensin
system and peripheral arterial disease. Search terms
included ‘renin–angiotensin system’, ‘angiotensin-
converting enzyme (ACE) inhibitors’, ‘angiotensin
receptor blockers’ or ‘renal artery stenosis’ combined,
where possible, with ‘peripheral vascular/arterial
disease’. Cross-referencing from the reference lists of
major relevant articles identified further papers. All
relevant abstracts were reviewed and relevant papers
were assessed in more detail.Renin–angiotensin system
The renin–angiotensin system acts acutely to regulate
effective circulating volume and blood pressure in
response to hypotension, hypovolaemia, haemorrhageEur J Vasc Endovasc Surg 28, 573–582 (2004)
doi:10.1016/j.ejvs.2004.08.003, available online at http://www.sciencedirect.com onved.
S. D. Hobbs et al.574and heart failure.6 In the longer term, Angiotensin
(Ang)-II has also been shown to have significant pro-
inflammatory and pro-atherogenic properties.7 Renin
is produced by the juxta-glomerular apparatus
(specialised myoepithelial cells of the glomerular
afferent arteriole), and released into the afferent
arteriole and surrounding interstitial tissue principally
in response to reduced renal perfusion, stimulation of
the renal sympathetic nerves and low plasma sodium.
Renin acts upon angiotensinogen (an a2-globulin
produced by the liver) to form the decapeptide Ang-
I, which is cleaved to the octapeptide Ang-II by ACE
(Fig. 1). ACE is selectively localised on the surface of
endothelial cells and much of the circulating Ang-I is
cleaved to Ang-II is formed in the lungs.Systemic actions of angiotensin II
Ang-II has wide ranging effects on a number of body
organs. Specifically it causes:†Eusystemic vasoconstriction, so increasing systemic
arterial blood pressure by acting on smooth muscle
angiotensin-1R receptors and causing the local
release of endothelin-1 from endothelial and
smooth muscle cells,8† preferential constriction of the efferent arterioles so
helping to maintain a constant glomerular capillary
pressure, and hence glomerular filtration rate (GFR)
in the face of reduced renal perfusion; for example,
as in renovascular disease,† sodium absorption from the proximal convoluted
tubule leading to increased circulating volume and
total body water,† aldosterone release from the adrenal cortex resulting
in increased sodium (and thereby water) reabsorp-
tion from the distal convoluted tubules in the kidney,† antidiuretic hormone (ADH) release from the
posterior pituitary gland resulting in enhancedFig. 1. The renin–angiotensin system.
r J Vasc Endovasc Surg Vol 28, December 2004water reabsorption in the collecting ducts via a
synergistic effect with aldosterone,† thirst by acting on Ang-II receptors in the brain.Proatherogenic effects of angiotensin II
Ang-II also enhances atherogenesis, especially in the
presence of hyperlipidaemia,7 by stimulating the:† migration, proliferation and hypertrophy of smooth
muscle cells,9† production of monocyte attractant protein-1 by
smooth muscle cells and expression of vascular
cell adhesion molecule-1, leading to the recruitment
of monocytes and macrophages into the vessel,10† accumulation of extracellular matrix through the
production of transforming growth factor-b,11† superoxide production within the vascular wall via
NADH/NADPH dependent enzyme pathways,
thereby increasing the oxidation of LDL.12Angiotensin receptors
Ang-II exerts its effect via two receptors (Ang-1R and
Ang-2R), both of which belong to the 7-transmem-
brane G-protein coupled receptor family that have
quite different characteristics and distribution.6 Ang-
1R predominates in the adult and is widely expressed
on endothelial cells, monocytes and vascular smooth
muscle cells.13 Ang-2R predominates in the foetus and
has important developmental functions. In the adult,
Ang-2R is mainly expressed in the adrenals, ovaries,
uterus and brain but its function is not well
established.6
The pro-atherogenic actions of Ang-II discussed
above appear to be primarily mediated via Ang-1R
and blockade of this receptor may be beneficial in
patients with, and at risk of vascular disease.7Bradykinin
ACE (also known as kinase II) also has important
regulatory functions within the kallikrein–kinin sys-
tem by catalysing the degradation of bradykinin.14
Bradykinin tends to antagonise the effects of angio-
tensin II, predominantly via its activation of the
bradykinin B2 receptor. Increased levels of bradykinin
induces:† vasodilatation by causing the release of vasodila-
tory agents such as nitric oxide (NO), prostacyclin
and endothelium-derived hyperpolarising factor,15
ACE Inhibitors and Arterial Disease 575† inhibition of platelet adhesion and aggregation and
inhibition of smooth muscle migration and
proliferation,6† natriuresis via a direct tubular effect within the
kidney.
Through these actions bradykinin is able to
antagonise the proatherogenic actions of Ang-II and
produce an overall effect of plaque stabilisation.6Angiotensin-converting enzyme inhibitors
The HOPE study was a double-blind randomised
study evaluating ramipril (Titracew, Aventis Pharma)
in 9297 patients, over the age of 55 years, with a history
of coronary heart disease, stroke, PAD or a history of
diabetes plus at least one other risk factor (hyperten-
sion, elevated total cholesterol or LDL levels, cigarette
smoking, or documented microalbuminuria).5 The
study included a cohort of 4051 (44%) patients with
PAD defined as:1. previous limb bypass surgery or percutaneous
angioplasty,2. previous limb or foot amputation,
3. history of intermittent claudication with ankle: arm
blood pressure !0.8 in at least one side or,
4. significant stenosis (O50%) documented by
angiography.16
Those with heart failure or a known ejection
fraction of !0.4 were excluded. Patients were ran-
domised to receive ramipril (titrated up to 10 mg) or
placebo. The primary endpoint was a composite of MI,
stroke or cardiovascular death.
At a mean follow-up of 4.5 years, ramipril signifi-
cantly reduced the composite end-point by 25%. As a
result, the study was terminated early due to the clear
evidence of a beneficial effect of ramipril after only 2
years. This reduction in risk was at least as large as that
observed for treatment with aspirin and lipid-low-
ering agents17,18 and was independent of entry blood
pressure. Interestingly, there was only a modest
reduction in blood pressure in the ramipril arm
(3 mmHg systolic and 2 mmHg diastolic pressure)
prompting the authors to suggest that the drug’s
antihypertensive properties could not completely
account for the observed risk reduction. An expla-
nation for this lack of relationship may be that in
HOPE, ramipril was taken in the evening and blood
pressure was recorded during the day at which time
the antihypertensive effects of the drug would have
waned (peak effect 3–6 h, waned by 12 h).19The implication of the above findings is that all
patients with clinical evidence of PAD should be
considered for ramipril as part of BMT.
The benefits of ACE inhibition in hypertension and
cardiac failure can be explained by a decrease in
cardiac afterload (reduced vasoconstriction) and pre-
load (reduced salt and water retention).20 It also
appears likely that ACE inhibitors have the potential
to stabilise atherosclerotic plaques.21 In patients with
coronary heart disease, non-insulin dependent dia-
betes and in hypertensive patients, ACE inhibition has
been shown to improve endothelial vasomotor dys-
function.22 Furthermore, in the Study to Evaluate
Carotid Ultrasound changes in patients treated with
Ramipril and vitamin E (SECURE), a sub study of
HOPE, ramipril reduced the intima-to-media ratio of
carotid arteries in patients at high risk for cardiovas-
cular events thus implying that ACE inhibition may be
able to initiate regression of atherosclerotic lesions.23
The biochemical mechanisms by which ACE inhibi-
tors achieve their vascular protective effects have been
comprehensively described by Faggiotto and Paoletti6
and the main actions are summarised in Table 1. It is of
interest that a number of these pleiotropic effects of
ACE inhibitors are also shared by the statins although
it has not yet been established whether combination
therapy with statins and ACE inhibitors will result in
additive or synergistic vascular effects.6Angiotensin receptor blockers (ARBs)
The sartanes (losartan, valsartan, irbesartan, cande-
sartan, eprosartan, olmesartan, and telmisartan) are
competitive Ang-1R antagonists currently licensed
for the treatment of hypertension and diabetic
nephropathy. They do not increase bradykinin and
are a suitable alternative for those patients with
hypertension who develop cough or angiodema as a
side effect of ACE inhibition. Current evidence
indicates that ARBs are better than placebo and
equivalent to ACE inhibitors in the treatment of
cardiac failure although they are not currently
licensed for this use.24,25 At the present time it
remains uncertain whether ARBs share the cardio-
protective and anti-atherosclerotic properties of ACE
inhibitors. The Optimal Trial in Myocardial Infarc-
tion with Angiotensin-II Antagonist Losartan (OPTI-
MAAL) compared losartan (Cozaarw, MSD) and
captopril (non-proprietary) in 5477 patients with
acute myocardial infarction and heart failure.26
Although losartan was better tolerated than captopril
there were significantly more cardiovascular deaths
in the losartan treated group. By contrast, theEur J Vasc Endovasc Surg Vol 28, December 2004
Table 1. The biochemical mechanisms by which ACE inhibitors achieve their vascular protective effects
† Inhibition of smooth muscle cell migration and proliferation50
† Inhibition of platelet adhesion and aggregation51
† Reduced oxidative stress and inhibition of LDL oxidation52
† Reduced accumulation of extra cellular matrix by inhibition of transforming growth factor-b11
† Stimulation of endothelial relaxation via stimulation of nitric oxide (NO) and prostacyclin (PGI2)53
† Inhibition of platelet-derived growth factor, endothelin and P-selectin expression54,55
† Reduced plasminogen-activator inhibitior-1 (PAI-1) leading to enhanced endogenous fibrinolysis56
S. D. Hobbs et al.576CHARM program of trials recently showed the
benefits of Candesartan (Amiasw, Astra Zenica) in
reducing cardiovascular mortality and heart failure
hospitalisation in certain types of patient with
symptomatic heart failure.27 Other ARB trials are
due to report in the near future.Renal Artery Stenosis in PAD
Although the HOPE study has shown that patients
with PAD treated with ramipril were 25% less likely to
suffer a cardiovascular events than those treated with
placebo, most patients remain untreated. There are
probably three main reasons for this.1.Tab
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EuIgnorance of the benefits of ACE inhibition.
2. Concerns about renal artery stenosis (RAS); and
possibly.
3. A general reluctance on the part of some vascular
surgeons to prescribe drugs.
In the presence of RAS adequate glomerular
perfusion is maintained by Ang-II dependentle 2. Summary of studies reporting the incidence of renal artery s
k groups
thor Date Population Imaging
modality
No. of
patients
tcalfe57 1999 PAD Angiography 218
lms58 1990 PAD Angiography 100
artbol59 1992 PAD Angiography 450
artbol60 1994 PAD Angiography 100
rin61 1997 PAD Angiography 418
ssouris33 1994 PAD Angiography 127
mon35 1990 PAD Angiography 374
oudri36 1990 PAD Angiography 100
chtell62 1996 PAD Angiography 100
rding63 1992 IHD Angiography 1235
n37 1994 IHD Angiography 196
mirez38 1987 IHD Angiography 102
roda64 2000 Stroke Post-mortem 346
AAA Post-mortem 46
icki31 1991 General
population
Post-mortem 5194
nsen32 2002 General
population
Duplex 834
Severe bilateral renal artery stenosis (O75%).
Renal artery stenosis of O75%.
Renal artery stenosisO60%.
r J Vasc Endovasc Surg Vol 28, December 2004vasoconstriction of the efferent arteriole. ACE inhi-
bition or Angiotensin receptor blockade results in
vasodilatation and a significantly decreased GFR.21 If
RAS is unilateral, GFR can be reduced ipsilaterally
while total GFR may remain normal. However, if the
RAS is bilateral there is a risk, but importantly by no
means a certainty, of renal failure.28 Interestingly,
although patients recruited into the HOPE study
would normally be considered to be at a relatively
high risk for RAS, the incidence of renal dysfunction
following initiation of ramipril was low with only
13/10,576 (0.12%) patients excluded before randomis-
ation as a result of a serum creatinine rise during a test
dose of 2.5 mg ramipril for 7–10 days.29 Furthermore,
during the course of the study, treatment had to be
stopped due to a rise in serum creatinine in only
22/4132 (0.5%) patients receiving ramipril compared
with 27/4175 (0.6%) receiving placebo.30Prevalence of renal artery stenosis
The major studies describing the incidence of RAS in
patients with PAD and other high-risk groups aretenosis in patients with peripheral arterial disease and other high-
Mean
age
25–50%
RAS (%)
O50%
RAS (%)
Bilateral
RAS (%)
RAS prevalence
(%)
65 36.2
22 22
71 26 25 12
68 30 19 49
67 27
71 17 16 12 45
50–85 17.1 13.9 11.5 31
67 17 11 24 28
69 17 14 4 31
60 15 15 4a 30
63 15 18 5a 33
55.6 8.8 4.9 1a 13.7
69 10.4b 2.9 10.4b
23.9b 23.9b
4.3 1.3 4.3
77.2 6.8c 6.8c
Table 3. Non-invasive techniques for screening for renal artery stenosis
Test Disadvantages Advantages
Colour duplex ultrasonography High intra-observer variability
High technical failure (obesity and bowel
gas)
Cheap
Newer technology may reduce problems
Renal scintigraphy with 99mTc mertiatide Low sensitivity and specificity
Spiral CT angiography Large volume of contrast required Excellent visualisation of renal arteries
Gadolinium enhanced
MRI angiography
Expensive
Limited visualisation of intra-renal arteries
Excellent visualisation of aorta and renal
arteries
No risk of contrast nephrotoxicity
ACE Inhibitors and Arterial Disease 577summarised in Table 2. RAS is, of course, significantly
under diagnosed on clinical grounds in patients with
vascular disease. In one autopsy series only 7% of
patients identified withO50% stenosis were known to
have RAS pre-mortem.31 Overall, it is estimated the
incidence of RAS in the general population over the
age of 65 years is in the region of 5%with the incidence
increasing with age.31,32 The incidence of RAS in
patients with PAD is between 20 and 50% in angio-
graphic series, with 12–24% having bilateral RAS.33–36
In practice, however, the incidence of RAS in unse-
lected patients with PAD is likely to be lower than this,
since the majority of patients with PAD do not have
disease severe enough to warrant angiography. By
way of comparison, in other high-risk groups the
prevalence of RAS from autopsy series is reported to
be 8.3 and 10.1% in normotensive and hypertensive
diabetics respectively and 33% among patients
undergoing cardiac catheterisation (15% mild (!50%
stenosis) and 18% significant (O50% stenosis)).37 The
incidence of RAS increases with increasing severity of
ischaemic heart disease.38Detection of renal artery stenosis
If one takes the view that mild to moderate RAS is a
contra-indication to ACE inhibition, even if there is no
real evidence to suggest that this is the case, then it isTable 4. Clinical factors predicting the presence of renal artery stenos
study40
Characteristic
Age
Male sex
Ever smoked
HypercholesterolaemiaO6.5 mmol/l
ObesityR25 kg/m2
Serum creatinine
Abdominal bruit
Recent onset hypertension (!2 years)
Atherosclerotic vascular disease (CHD, CVD, PAD)
CHD, coronary heart disease; CVD, cerebrovascular disease; PAD, per
a Per 10 year increase in age.
b Per 10 mmol/l increase in serum creatinine.relevant to ask whether such patients can be identified
either on the basis of imaging or clinical grounds.Imaging
Although angiography is the gold standard, the cost
and its invasive nature makes this unsuitable as a
screening tool. There are currently four main non-
invasive tools available to aid with the detection of
RAS and these are shown in Table 3. As no test for
renal artery stenosis has proved sufficiently accurate,
inexpensive, non-invasive and reproducible to act as a
screening tool and given the large number of patients
with PADwho would be expected to benefit fromACE
inhibition, it would be useful to be able to identify
those patients deemed to be at high risk on the basis of
clinical criteria.39Clinical prediction rules
The Dutch Renal Artery Stenosis Intervention Coop-
erative (DRASTIC) have developed a clinical predic-
tion rule to quantify the likelihood of a patient having
RAS of O50%.40 Four hundred and seventy seven
patients with drug resistant hypertension or a serum
creatinine rise following initiation of an ACE inhibitor,
and who underwent renal angiography were studied
to identify clinical characteristics that would predict
RAS. The resulting clinical prediction rule (Table 4)
comprises nine easily acquired clinical or laboratoryis. Based on the clinical prediction rule derived from the DRASTIC
Odds ratio
1.8a
0.4
1.6
1.7
0.4
1.4b
5.4
1.9
1.8
ipheral arterial disease
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Box 1
Abbreviated modified diet in renal disease (MDRD) equation (Eq. (4)). Demographic and serum
variables for the estimation of glomerular filtration rate (GFR, ml/min per 1.73 m2).42
MDRD Eq. (7). Demographic and serum variables for the estimation of glomerular filtration rate (GFR,
ml/min per 1.73 m2).42
Units: creatinine, mmol/l; urea, mmol/l; albumin, g/l.
S. D. Hobbs et al.578variables and is almost as accurate as renal scintigra-
phy (sensitivity 72%; specificity 90%).40ACE inhibitor prescribing in PAD
The HOPE study has provided compelling evidence
that the benefits of ACE inhibition in patients with
PAD far outweigh the risks. Nevertheless, vascular
surgeons remain wary of the small risk of precipitating
acute renal failure in patients with occult but never-
theless severe, bilateral RAS.41 Our strategy involves
identifying a subgroup of patients felt to be at high risk
of RAS and referring them to a nephrologist to exclude
significant renovascular disease and to advise whether
ACE inhibition is warranted. The criteria used to
identify such patients are based on the clinical
prediction rules and include:†EuDifficult hypertension and femoral/abdominal
bruits,† Difficult hypertension and GFR !50 ml/min per
1.73 m2,† GFR!50 ml/min per 1.73 m2 and femoral/abdom-
inal bruits,† GFR !25 ml/min per 1.73 m2,
GFR can be estimated using readily available
demographic and serum variables by the ‘abbreviated
MDRD’ equation or the slightly more accurate MDRD
Eq. (7) (Box 1).42 Although they involve power
functions, they do not require the patient’s weight.r J Vasc Endovasc Surg Vol 28, December 2004This latter feature and improved precision means they
have superseded the Cockcroft–Gault equation. Either
MDRD equation can be easily incorporated into a
computerised spreadsheet. The abbreviated equation
is now used for routine GFR reporting from creatinine
values measured in our Trust, and its use for this
purpose is likely to become widespread.
Only a minority of patients with intermittent
claudication seen in primary and secondary care will
fall into these categories and, therefore, the majority
can be considered for an ACE inhibitor. We commence
patients on ramipril according to our clinical algor-
ithm shown in Box 2. At initiation, the clinician needs
to particularly assess the concurrent medication (for
diuretic, potassium-sparing diuretic or non-steroidal
anti inflammatory drug use) and volume status of the
patient. Low blood pressure and any other evidence of
volume depletion (e.g. lack of oedema in a normally
oedematous patient) should be noted.
The next question to consider is how concerned
should we be by any rise in serum creatinine or
potassium? A rise in creatinine is known to be
associated with advanced age, use of diuretic
therapy43 or other forms of volume depletion/hypo-
tension, renovascular disease and non-steroidal drug
use.44,45 There are various patterns of worsening renal
dysfunction with ACE inhibition that should be
distinguished from each other (Fig. 2).
In patients with pre-existing CRF, an early rise in
serum creatinine of up to 30% with ACE inhibition is,
in fact, clearly linked to long-term renal protection
Box 2
Suggested algorithm for initiation of ramipril in patients with peripheral arterial disease
ACE Inhibitors and Arterial Disease 579(Fig. 2(A)).44 The mechanism is unknown, but it is
thought that ‘remnant’ or surviving nephrons may be
subject to deleterious hyperfiltration. ACE inhibition
may reduce hyperfiltration and thus glomerular
filtration, so the early fall in GFR may herald a
longer-term protective effect.
In contrast, in ACE inhibitor induced acute on
chronic renal failure (Fig. 2(B)) or acute renal failure(Fig. 2(C)) the rise in creatinine is over 50% and rapidly
progressive. We accept a rise in creatinine of up to 30%
from baseline levels, or in potassium of up to
5.9 mmol/l, after starting ACE inhibition in patients
with peripheral arterial disease. This is in line with
other recommendations.44–46 The finding of a rise of
greater than 30% in creatinine should lead to
cessation of ACE inhibitor therapy, a search forEur J Vasc Endovasc Surg Vol 28, December 2004
Fig. 2. Patterns of creatinine change with ACE inhibitor use (modified from Bakris and Weir, 2000).44
S. D. Hobbs et al.580hypotension, volume depletion, and nephrotoxin use.
Consideration should also be given to the possibility
of renovascular disease.Side effects of ACE inhibitors
In common with all antihypertensives, ACE inhibitors
may result in hypotension; especially in patients with
renin-dependent hypertension who are volume-
depleted due to either concomitant diuretic use or
sodium restriction.47 As a result of a reduction in
circulating aldosterone, ACE inhibitors may lead to
hyperkalaemia; especially in patients with chronic
renal failure and in those taking potassium sup-
plements, potassium-sparing diuretics or non-ster-
oidal anti inflammatory drugs.
A dry cough occurs in 5–15% of patients taking
ACE inhibitors. This is thought to be related to
increased levels of bradykinin or substance P,48
although in some cases it is as a result of
pulmonary congestion which responds to diuresis.12
Another side effect thought to be mediated via
bradykinin is angiodema which has an incidence of
1 per 1000.49Summary
In summary, therefore, we suggest that, in light ofEur J Vasc Endovasc Surg Vol 28, December 2004current evidence, ACE inhibitors should be prescribed
according to the above algorithm to patients with PAD
with confidence providing that a little caution is
maintained. Despite a small risk of reversible renal
deterioration in some patients, ACE inhibition has the
potential to significantly reduce the incidence of
cardiovascular events in this high-risk patient group
to a similar extent to that seen with anti-platelet agents
and statins. Whether this effect is additive remains to
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